Bank of America Begins Coverage on Kestra Medical Technologies (NASDAQ:KMTS)

Analysts at Bank of America assumed coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report released on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Bank of America‘s target price suggests a potential upside of 22.05% from the stock’s current price.

Other research analysts have also issued reports about the stock. Wells Fargo & Company began coverage on shares of Kestra Medical Technologies in a report on Monday. They set an “overweight” rating and a $28.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Kestra Medical Technologies in a research note on Monday. They set a “neutral” rating and a $24.00 price target on the stock. Piper Sandler started coverage on shares of Kestra Medical Technologies in a research note on Monday. They set an “overweight” rating and a $27.00 price objective for the company. Wolfe Research started coverage on Kestra Medical Technologies in a research report on Monday. They issued an “outperform” rating and a $29.00 target price on the stock. Finally, Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a research report on Monday. They set a “buy” rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Kestra Medical Technologies Trading Down 1.4 %

Kestra Medical Technologies stock opened at $24.58 on Monday. Kestra Medical Technologies has a 52 week low of $20.00 and a 52 week high of $25.98.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.